Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 787

    1.

    Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

    Laterre PF, Macias WL, Janes J, Williams MD, Nelson DR, Girbes AR, Dhainaut JF, Abraham E.

    Crit Care. 2008;12(5):R117. Epub 2008 Sep 11.

    PMID:
    18786266
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

    Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

    Crit Care Med. 2008 Jan;36(1):14-23.

    PMID:
    18158435
    [PubMed - indexed for MEDLINE]
    3.

    Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.

    Vincent JL, O'Brien J Jr, Wheeler A, Wittebole X, Garg R, Trzaskoma BL, Sundin DP.

    Crit Care. 2006;10(3):R74. Epub 2006 May 9.

    PMID:
    16684364
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    4.

    Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

    Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH.

    Health Technol Assess. 2005 Mar;9(11):1-126, iii-iv.

    PMID:
    15774234
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    [PROWESS, ENHANCE and ADDRESS: clinical implications for the treatment with drotrecogin alfa (activated)].

    Cobas Meyer M, Langenfeld H, Rossaint R, Sablotzki A.

    Anaesthesist. 2006 Jun;55 Suppl 1:16-23. Review. German.

    PMID:
    16680442
    [PubMed - indexed for MEDLINE]
    6.

    The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

    Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2004 Nov;32(11):2199-206.

    PMID:
    15640631
    [PubMed - indexed for MEDLINE]
    7.

    Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.

    Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF; PROWESS Clinical Evaluation Committee.

    Crit Care Med. 2005 May;33(5):952-61.

    PMID:
    15891319
    [PubMed - indexed for MEDLINE]
    8.

    Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

    Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators.

    Chest. 2004 Jun;125(6):2206-16.

    PMID:
    15189943
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.

    Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC.

    Crit Care Med. 2004 Nov;32(11):2207-18.

    PMID:
    15640632
    [PubMed - indexed for MEDLINE]
    10.

    From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).

    Short MA, Schlichting D, Qualy RL.

    Curr Med Res Opin. 2006 Dec;22(12):2525-40. Review.

    PMID:
    17265595
    [PubMed - indexed for MEDLINE]
    11.

    Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).

    Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J.

    Crit Care. 2008;12(2):R45. Epub 2008 Apr 4. Review.

    PMID:
    18394162
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

    Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2003 Jan;31(1):12-9.

    PMID:
    12544987
    [PubMed - indexed for MEDLINE]
    13.

    Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis.

    Macias WL, Vallet B, Bernard GR, Vincent JL, Laterre PF, Nelson DR, Derchak PA, Dhainaut JF.

    Crit Care Med. 2004 Dec;32(12):2385-91.

    PMID:
    15599140
    [PubMed - indexed for MEDLINE]
    14.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

    Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61.

    PMID:
    17084715
    [PubMed - indexed for MEDLINE]
    15.

    Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

    N Engl J Med. 2005 Sep 29;353(13):1332-41.

    PMID:
    16192478
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    Drotrecogin alfa (activated): real-life use and outcomes for the UK.

    Rowan KM, Welch CA, North E, Harrison DA.

    Crit Care. 2008;12(2):R58. Epub 2008 Apr 22.

    PMID:
    18430215
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    17.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

    Surgery. 2007 Apr;141(4):548-61.

    PMID:
    17431957
    [PubMed - indexed for MEDLINE]
    18.

    Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.

    [No authors listed]

    Prescrire Int. 2007 Feb;16(87):7-9.

    PMID:
    17323514
    [PubMed - indexed for MEDLINE]
    19.

    The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.

    Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, Beale R.

    Crit Care. 2009;13(3):R103. Epub 2009 Jun 30.

    PMID:
    19566927
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.

    Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D.

    Crit Care Med. 2003 Sep;31(9):2291-301.

    PMID:
    14501959
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk